Every week, something new promises to slow or reverse aging: a supplement with a glowing podcast review, a clinic therapy that "scientists" say works, a headline an executive wants in the benefits plan by next quarter. If you lead benefits or wellness, you will be asked about all of it, and evaluating longevity treatments quickly and fairly becomes part of the job.
The challenge is that, in longevity, confidence and evidence often run in opposite directions. The loudest claims tend to have the thinnest proof, while the best-proven interventions are quiet and unglamorous. Judge by how sure someone sounds, and you will be fooled.
This guide to evaluating longevity treatments lays out the Evidence-Tiering Framework taught in the Certified Corporate Longevity Specialist™ (CCLS) program: three tiers, four questions and a calm, honest posture you can use in any conversation. You do not need a clinical background to use it.
Why benefits leaders need a method for judging longevity claims
The CCLS™ course calls this framework the keystone skill. Your knowledge of the science, your measurement strategy and your executive business case all collapse the moment you endorse something that turns out to be hype. One bad recommendation can cost you your credibility and your program.
A method also protects your people. Some unproven products are merely a waste of money. Others carry real risk. Regulators have documented serious injuries from unproven stem cell products sold for aging, and several widely marketed peptides are not FDA-approved and have drawn regulator warnings. The person who can calmly sort these claims is standing between employees and a noisy, sometimes predatory market.
The three evidence tiers
Every therapy, supplement, device or test goes into one of three tiers. The tier determines how you talk about it.
- Established. Strong human evidence, repeated, ideally in large or randomized studies confirmed by more than one group. Action: recommend with confidence. Most of this tier is unglamorous: exercise and strength training, quality nutrition, good sleep, not smoking, managing blood pressure, ApoB and blood sugar, and proven medical screenings.
- Emerging. Real scientific signal, often strong lab or animal results and sometimes early human data, but not yet large, long-term human trials. Action: discuss with honest curiosity, never promise. Examples from the course include senolytics, certain repurposed drugs under active human study, some peptide therapies, multi-cancer detection blood tests and whole-body MRI.
- Unproven. Little or no real human evidence, supported by testimonials, anecdotes or marketing. Action: be skeptical and protect people. This includes most miracle anti-aging supplements, unregulated stem cell clinics, online "research peptides" and anything promising to reverse aging.
One essential point: tiers are not permanent. Today's emerging therapy can become tomorrow's established one when good human trials arrive. Placing something in the emerging tier is not dismissing it. It is saying "not yet proven, and we are watching." That willingness to update is what makes an advisor trustworthy.
Four questions for evaluating any longevity treatment
Knowing the tiers is one thing. Placing a new claim quickly is the real skill, and it comes down to four questions:
- Proven in whom? Humans, or just cells and mice? Animal results are exciting but rarely translate directly to people.
- For how long? A few weeks, or years? Longevity is a long game, so short studies prove little about aging.
- Compared to what? A real control group, or nothing? People improve for many reasons. No control, no proof.
- Who says so? Independent researchers, or the person selling the product? Watch the conflict of interest.
The questions in action
Imagine a claim lands on your desk: "This supplement reverses aging." Proven in whom? Mostly mice. For how long? A few weeks. Compared to what? No real control. Who says so? The company selling it. Four questions, and it lands clearly in the unproven tier. You did not need to understand the biochemistry. You needed the questions and the discipline to ask them.
The same questions cut through headlines. "Scientists reverse aging" often means in mice, in one tissue, in a lab. Cellular reprogramming is a genuine and remarkable finding, but the course describes it as almost entirely pre-human. Real, exciting and years away from your executive's clinic.
Sort the compound, not the category
Broad labels such as "peptide," "hormone" or "stem cell" tell you almost nothing. A single category can span all three tiers.
Stem cells are the clearest example. Bone marrow transplants for blood cancers are established medicine with decades of evidence. Specific, regulated trials for particular conditions are emerging. Direct-to-consumer infusions marketed for anti-aging are unproven and can be risky.
Likewise, GLP-1 medications are technically peptides and sit in the established tier for their approved uses, backed by large randomized trials. The peptides sold online as "research peptides" mostly have animal data and almost no rigorous human trials. Same word, very different evidence.
That leads to a second nuance: proven for a diagnosed condition is not the same as proven for anti-aging in everyone. Hormone therapy for a real, diagnosed deficiency, used under medical care, is established. The same hormones used broadly for vague anti-aging is a different and weaker claim. So the master move is two questions: which specific compound, and what is it actually proven for?
Traps and hard cases to watch for
The course names three traps that catch even careful people:
- The expert's word. A famous name endorses it. Credentials are not evidence.
- The mechanism trap. It sounds scientific, so it must work. A plausible story is not proof.
- The anecdote. It worked for a colleague. One story is not a study.
A useful instinct: the more heavily something is advertised to you, the more carefully you should check the evidence. Proven fundamentals rarely need to shout.
Some situations are genuinely gray. When an executive wants to try an emerging therapy anyway, you neither forbid nor endorse. You share what is known, what is not, and the risks and costs, and you make clear the decision belongs to them and their physician. When respected experts disagree, say so plainly. When a trusted clinical partner offers an emerging service, hold it to the same tiers. Our guide to choosing a longevity clinic partner covers how to build that standard into the relationship.
The skill underneath all of these is separating the evidence question from the decision. Your job is to assess the evidence honestly. The choice to act on it belongs to the individual and their doctor. A CCLS™ professional coordinates and translates. They never diagnose, treat or recommend specific therapies.
Talking about evidence so people listen
Let your language match the tier. For established: "This is well proven. I recommend it confidently." For emerging: "This is promising and still being studied. Worth watching, not yet proven." For unproven: "The evidence isn't there yet. I'd be cautious and focus elsewhere first."
Better still, show your reasoning. When someone asks about a therapy, walk them through the four questions. They start using the framework themselves, and over time you become the person colleagues check with before they spend money. And remember that "I don't know yet" is a complete, professional answer. Apply the same standard to your own favorite ideas, too. For a grounding in what the established tier actually measures, see longevity biomarkers explained, and for why all of this ultimately serves healthspan rather than lifespan, start there.
Key takeaways
- In longevity, confidence and evidence are often inversely related. Judge by evidence.
- Three tiers: established (recommend), emerging (discuss, never promise), unproven (be skeptical, protect people).
- Four questions sort almost anything: proven in whom, for how long, compared to what, and who says so.
- Sort by the specific compound and what it is proven for, never by the category label.
- Separate the evidence question from the decision, and route medical decisions to a physician.
The Evidence-Tiering Framework has its own dedicated module in the CCLS™ program, created by Jonathan Edelheit and issued by the Corporate Health & Wellness Association with Healthcare Revolution. It then guides a full tour of the longevity landscape. See all 13 modules or enroll today to make this lens your own.
Frequently asked questions
What is the Evidence-Tiering Framework?
It is the method the CCLS program uses to judge any longevity intervention. Every claim is placed in one of three tiers: established (strong, repeated human evidence, recommend with confidence), emerging (real signal but incomplete proof, discuss but never promise) or unproven (little real evidence, be skeptical and protect people). Tiers can change as new evidence arrives.
How can a non-clinician evaluate a longevity treatment?
Ask four questions of any claim. Proven in whom: humans, or only cells and mice? For how long: weeks or years? Compared to what: a real control group, or nothing? Who says so: independent researchers, or the company selling it? These questions let you judge the evidence without needing to understand the underlying biochemistry.
Are emerging longevity therapies safe to offer employees?
Emerging means promising but not yet proven in large, long-term human trials. Employers and benefits teams should not promise or endorse them. If an individual is interested, the honest approach is to share what is known and unknown and route the decision to that person and their physician.
About this article. Written by the CCLS editorial team, drawing on the curriculum of the Certified Corporate Longevity Specialist™ program, issued by the Corporate Health & Wellness Association in partnership with Healthcare Revolution. Learn who created the program.
This article is for general education for employers and benefits professionals. It is not medical advice. Individuals should talk with a qualified clinician about their own health.